Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Abstract Background Several phase 3 studies reported positive results for combinations of Immune-Oncology (IO) and Vascular Endothelial Growth Factor (VEGF) targeted therapies in patients with metastatic clear cell Renal Cell Carcinoma (ccRCC). However, there are limited data on outcomes to systemic...

Full description

Bibliographic Details
Main Authors: Yasser Ged, Ruby Gupta, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha, Martin H. Voss, Darren R. Feldman, Oguz Akin, Sujata Patil, Robert J. Motzer, Brian I. Rini, Chung-Han Lee
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Urology
Subjects:
Immune-oncology
IO combinations
RCC
VEGF
Survival
Online Access:http://link.springer.com/article/10.1186/s12894-020-00647-w

Internet

http://link.springer.com/article/10.1186/s12894-020-00647-w

Similar Items